Bigmar Raises $5 Million in New Financing.

JOHNSTOWN, Ohio--(BUSINESS WIRE)--Sept. 12, 1997--Bigmar, Inc. (Nasdaq:BGMR/Boston Stock Exchange:BGM) announced today that it has received $5,000,000 in new financing from Banca del Gottardo, Lugano, Switzerland, comprised of a private placement of common stock and convertible notes. Proceeds will be used for general corporate purposes and working capital.

John J. Tramontana, President and CEO of Bigmar, stated, "We appreciate the confidence this European bank has shown in Bigmar's future potential. These funds, together with the Company's line of credit and working capital, will further support our aggressive efforts to manufacture and commercialize additional generic oncological products."

Forward-looking statements involve known and unknown risks, uncertainties and other factors as detailed in the Company's SEC reports and filings, which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied in such forward-looking statements.

BIGMAR, Inc.'s strategy is to supply world markets with a full line of high-quality, affordably priced generic and proprietary oncology products. With distribution rights to more than 20 generic oncological products, the Company intends to manufacture, in its state-of-the-art facilities in Switzerland, and market through pharmaceutical company partners in Europe and the United States off- patent generic oncological drugs and additional oncological drugs as their patents expire.

CONTACT: Bigmar, Inc.

Michael K. Medors, CFO 

[phone]

or

Bigmar's Investor Relations Counsel:

The Equity Group Inc.

Tamara Ehlin [phone]

email: [e-mail]